Leland Metheny
Clinical trials sponsored by Leland Metheny, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Edited stem cells may let doctors use stronger chemo against brain cancer Results expected Nov 2026 (estimated)
- Inotuzumab ozogamicin Post-Transplant for acute lymphocytic leukemia Results expected Nov 2026 (estimated)
-
Gene-Edited stem cells may let doctors use stronger chemo against brain cancer
Disease control Recruiting nowThis study tests a new approach for people with a recently removed glioblastoma (a fast-growing brain tumor). Doctors take some of the patient's own blood stem cells, add a protective gene (P140K MGMT) to them, and return them to the patient. This allows the use of higher doses o…
Phase 2 • Sponsor: Leland Metheny • Aim: Disease control
Last updated Sep 10, 2026 16:00 UTC
-
Inotuzumab ozogamicin Post-Transplant for acute lymphocytic leukemia
Recruiting nowThis study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to …
Phase 1/2 • Sponsor: Leland Metheny
Last updated Sep 10, 2026 16:00 UTC